We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
Read MoreHide Full Article
Key Takeaways
Bayer has filed an NDA with the FDA for gadoquatrane, a low-dose gadolinium MRI contrast agent.
Gadoquatrane cuts gadolinium dose by about 60% compared to current macrocyclic GBCAs.
QUANTI studies showed gadoquatrane improves image quality with no new safety concerns in adults or children.
Bayer (BAYRY - Free Report) announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in contrast-enhanced magnetic resonance imaging (“MRI”) of the central nervous system and other body regions for adults and pediatric patients, including term neonates.
The proposed dose of 0.04 mmol gadolinium per kilogram (Gd/kg) represents a substantial reduction, approximately 60%, compared to the current standard of care, which is macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight.
Earlier this month, Bayer submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare (“MHLW”) for gadoquatrane. The MRI contrast agent is intended to enhance imaging of suspected or known conditions across all body regions in both adults and pediatric patients, including neonates.
Year to date, shares of Bayer have rallied 58% compared with the industry’s rise of 2.6%.
Image Source: Zacks Investment Research
Potential Nod to Gadoquatrane to Expand BAYRY's Portfolio
The NDA submission was based on positive data from the pivotal phase III QUANTI studies, which evaluated the safety and efficacy of gadoquatrane in adult and pediatric patients worldwide.
The QUANTI study confirmed that gadoquatrane effectively met both its primary and secondary efficacy endpoints in improving image quality and helping identify lesions during scans. These results support its potential as a reliable contrast agent for accurate diagnosis.
Also, data from the QUANTI Pediatric study, which is part of the QUANTI studies, showed that gadoquatrane behaves the same way in children as it does in adults. It was also found to be generally safe for both age groups, with no new safety concerns reported.
The need for medical imaging is growing, mainly because more people are getting chronic diseases like cancer and heart problems.
If approved, gadoquatrane would become the lowest-dose macrocyclic GBCA to be available in the United States, further strengthening Bayer’s leadership in the field of radiology.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.61 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.83 to $3.03. Year to date, shares of EXEL have increased 24.2%.
EXEL’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 48.60%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.00 to $2.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $3.87 to $1.78. Year to date, shares of AMRN have surged 38.3%.
AMRN’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 29.11%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 46 cents to 51 cents. Year to date, shares of PBYI have risen 12.5%.
PBYI’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 171.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
Key Takeaways
Bayer (BAYRY - Free Report) announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in contrast-enhanced magnetic resonance imaging (“MRI”) of the central nervous system and other body regions for adults and pediatric patients, including term neonates.
The proposed dose of 0.04 mmol gadolinium per kilogram (Gd/kg) represents a substantial reduction, approximately 60%, compared to the current standard of care, which is macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight.
Earlier this month, Bayer submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare (“MHLW”) for gadoquatrane. The MRI contrast agent is intended to enhance imaging of suspected or known conditions across all body regions in both adults and pediatric patients, including neonates.
Year to date, shares of Bayer have rallied 58% compared with the industry’s rise of 2.6%.
Image Source: Zacks Investment Research
Potential Nod to Gadoquatrane to Expand BAYRY's Portfolio
The NDA submission was based on positive data from the pivotal phase III QUANTI studies, which evaluated the safety and efficacy of gadoquatrane in adult and pediatric patients worldwide.
The QUANTI study confirmed that gadoquatrane effectively met both its primary and secondary efficacy endpoints in improving image quality and helping identify lesions during scans. These results support its potential as a reliable contrast agent for accurate diagnosis.
Also, data from the QUANTI Pediatric study, which is part of the QUANTI studies, showed that gadoquatrane behaves the same way in children as it does in adults. It was also found to be generally safe for both age groups, with no new safety concerns reported.
The need for medical imaging is growing, mainly because more people are getting chronic diseases like cancer and heart problems.
If approved, gadoquatrane would become the lowest-dose macrocyclic GBCA to be available in the United States, further strengthening Bayer’s leadership in the field of radiology.
BAYRY's Zacks Rank & Other Stocks to Consider
Bayer currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Exelixis (EXEL - Free Report) , Amarin Corporation (AMRN - Free Report) and Puma Biotechnology (PBYI - Free Report) each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.61 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.83 to $3.03. Year to date, shares of EXEL have increased 24.2%.
EXEL’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 48.60%.
In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.00 to $2.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $3.87 to $1.78. Year to date, shares of AMRN have surged 38.3%.
AMRN’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 29.11%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 46 cents to 51 cents. Year to date, shares of PBYI have risen 12.5%.
PBYI’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 171.43%.